NL-OMON46416已完成2 期
A Double-masked, Placebo-controlled Study with Open-label Period to Evaluate the Efficacy and Safety of MEDI-551 in Adult Subjects with Neuromyelitis Optica and Neuromyelitis Optica Spectrum Disorders. - N-MOmentum
适应症
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 3
研究概览
简要总结
Trial ended prematurely
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 99（—）
入选标准
- •1) Men and women 18 years or older with diagnosis of NMO/NMOSD.
- •2) Confirmation of NMO/NMOSD status:
- •a.) AQP4-IgG sero-positive NMO/NMOSD with at least one attack requiring rescue
- •therapy in the last year or two attacks requiring rescue therapy in the last 2 years.
- •b.) AQP4-IgG sero-negative NMO with at least one attack requiring rescue therapy in the last year or two attacks requiring rescue therapy in the last 2 years.
- •3) EDSS <= 7.5 (8 in special circumstances).
- •4) Men and women of reproductive potential must agree to use a highly effective method of birth control from screening to 6 months after final dose of the investigational product.
排除标准
- •1) Lactating and pregnant females.
- •2) Treatment with any investigational agent within 4 weeks of screening.
- •3) Known history of a severe allergy or reaction to any component of the investigational product formulation or history of anaphylaxis following any biologic therapy.
- •4) Known active severe bacterial, viral, or other infection or any major episode of infection requiring hospitalization.
- •5) History of of alcohol, drug, or chemical abuse, or a recent history of such abuse < 1 year prior to randomization.
- •6) Receipt of the following at any time prior to randomization:
- •a) Alemtuzumab
- •b) Total lymphoid irradiation
- •c) Bone marrow transplant
- •d) T-cell vaccination therapy
- •7) Receipt of rituximab or any experimental B-cell depleting agent within 6 months prior screening and B-cells below the lower limit of normal.
- •8) Receipt of IVIG within 1 month prior to randomization.
- •9) Receipt of any of the following within 3 months prior to randomization:
- •a) Natalizumab (Tysabri®)
- •b) Cyclosporin
- •c) Methotrexate
- •d) Mitoxantrone
- •e) Cyclophosphamide
- •f) Tocilizumab
- •g) Eculizumab
- •10) History of Hepatitis B and/or Hepatitis C (Hep B/C at screening).
- •11) Known history of a primary immunodeficiency (congenital or acquired) or an underlying condition such as human immunodeficiency virus (HIV) infection.
- •12) History of malignancies, apart from squamous cell or basal cell carcinoma of the skin treated with documented success of curative therapy > 3 months prior to randomization.
- •13) Any concomitant disease other than NMO/NMOSD that required treatment with oral or intravenous steroids at doses over 20 mg a day for over 21 days.
研究者
相似试验
已完成
不适用
A Phase 1, Randomized, Placebo-Controlled, Double-Blind, First in Man, Single Escalating Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of GAL-475 in Healthy Male Volunteers and Male Subjects with Sleep Apneasleep disorderSleep apneaNL-OMON55229eurim Pharmaceuticals Ltd.36
已完成
2 期
A randomized, placebo-controlled, double-blind, parallel-group, multi-center, exploratory dose-response study to assess the efficacy and safety of different oral doses of BAY1128688 in women with symptomatic endometriosis over a 12-week treatment periodpain during intercourse ('dyspareunia') and non-cyclic pelvic pain.Well-accepted lay language synomyms for endometriosis are not known to us. Endometriosis describes the presence of endometrium elsewhere than in the lining of the uterus. It is associated with pelvic pain during menstruation called 'dysmenorrhea'10038612NL-OMON46660Bayer5
已完成
2 期
A Phase 2, Randomized, Double-Blind, Placebo-Controlled Efficacy and Safety Study of Palovarotene in Subjects with Multiple OsteochondromasNL-OMON48469Clementia Pharmaceuticals Inc10
已完成
不适用
Extension of the randomized, double-blind, placebo-controlled single ascending dose study to assess the safety and tolerability of AP30663 in healthy subjects.Atrial fibrillationsupraventricular tachycardiaNL-OMON49415Acesion Pharma ApS32
已完成
不适用
A phase I, randomised, double-blind, placebo-controlled study in patients with amyotrophic lateral sclerosis to further assess the safety and tolerability of intracerebroventricular administration of sNN0029 infusion solution.ALSLou Gehrig's disease1002930510009720NL-OMON40611ewron Sweden AB9